• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2012 Product Image

Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2012

  • ID: 2298864
  • October 2012
  • 41 pages
  • Global Markets Direct

Athlete's Foot (Tinea Pedis) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis). Athlete's Foot (Tinea Pedis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Athlete's Foot (Tinea Pedis).
- A review of the Athlete's Foot (Tinea READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Athlete's Foot (Tinea Pedis) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Athlete's Foot (Tinea Pedis) 7
Athlete's Foot (Tinea Pedis) Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Athlete's Foot (Tinea Pedis) Therapeutics – Products under Development by Companies 14
Companies Involved in Athlete's Foot (Tinea Pedis) Therapeutics Development 15
Stiefel Laboratories, Inc. 15
Quinnova Pharmaceuticals, Inc. 16
Helix BioMedix, Inc. 17
Almirall, S.A. 18
Anacor Pharmaceuticals, Inc. 19
Nitric Biotherapeutics, Inc. 20
Laboratorio Teuto Brasileiro 21
Athlete's Foot (Tinea Pedis) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
HB-1275 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AN-2718 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
albaconazole - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LAS-41003 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
nitric oxide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
econazole nitrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
tolnaftate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Athlete's Foot (Tinea Pedis) Therapeutics – Drug Profile Updates 36
Athlete's Foot (Tinea Pedis) Therapeutics - Dormant Products 37
Athlete's Foot (Tinea Pedis) – Product Development Milestones 38
Featured News & Press Releases 38
Sep 12, 2012: Topica Pharma Presents Findings From Phase I/IIa Trial Of Luliconazole Solution In Onychomycosis At ICAAC 2012 38
Apr 12, 2006: Medicis Announces Two Patents Issued for Loprox Gel 38
Dec 20, 1999: Medicis Announces FDA Approval of Loprox Gel, 0.77% 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Athlete's Foot (Tinea Pedis), H2 2012 7
Products under Development for Athlete's Foot (Tinea Pedis) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Stiefel Laboratories, Inc., H2 2012 15
Quinnova Pharmaceuticals, Inc., H2 2012 16
Helix BioMedix, Inc., H2 2012 17
Almirall, S.A., H2 2012 18
Anacor Pharmaceuticals, Inc., H2 2012 19
Nitric Biotherapeutics, Inc., H2 2012 20
Laboratorio Teuto Brasileiro, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Athlete's Foot (Tinea Pedis) Therapeutics – Drug Profile Updates 36
Athlete's Foot (Tinea Pedis) Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Athlete's Foot (Tinea Pedis), H2 2012 7
Products under Development for Athlete's Foot (Tinea Pedis) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos